A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348(2)
An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of CKD-348(2) with coadministration of CKD-828, D097 and D337 in healthy adult volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
62
QD, PO
QD, PO
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea
AUCt of CKD-348(2)
AUCt: Area under the concentration-time curve from time zero to time
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
Cmax of CKD-348(2)
Cmax: Maximum plasma concentration of the drug
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
AUCinf of CKD-348(2)
AUCinf: Area under the concentration-time curve from zero up to ∞
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
Tmax of CKD-348(2)
Tmax: Time to maximum plasma concentration
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
AUCt/AUCinf of CKD-348(2)
AUCt/AUCinf
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
T1/2 of CKD-348(2)
T1/2: Terminal elimination half-life
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.